Desmoid Tumor Highlights From CTOS 2024

CME

Independent Conference Highlights of the 2024 CTOS Annual Meeting: Perspectives on Emerging Data in Desmoid Tumors

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: February 20, 2025

Expiration: August 19, 2025

Activity

Progress
1 2
Course Completed

References

  1. Gounder M, Ratan R, Alcindor T, et al. Nirogacestat, a γ-secretase inhibitor for desmoid tumors. N Engl J Med. 2023;388:898-912.
  2. Ratan R. DeFi: long-term follow-up of nirogacestat for adults with desmoid tumors. Presented at the Connective Tissue Oncology Society Annual Meeting; November 13-16, 2024. Abstract 103.
  3. ‌Vincenzi B. DeFi: subgroup analysis of nirogacestat efficacy in patients with desmoid tumors and poor prognostic factors. Presented at the Connective Tissue Oncology Society Annual Meeting; November 13-16, 2024. Abstract 102.
  4. Singh V. Retrospective real-world study of nirogacestat in patients with desmoid tumors. Presented at the Connective Tissue Oncology Society Annual Meeting; November 13-16, 2024. Abstract 35.
  5. Boye K. Population-based study of pegylated liposomal doxorubicin in patients with symptomatic desmoid tumors. Presented at the Connective Tissue Oncology Society Annual Meeting; November 13-16, 2024. Abstract P40.
  6. Lominchar L. Multidisciplinary care of patients with primary, intra-abdominal desmoid fibromatosis: ​a single-institution 30-yr experience. Presented at the Connective Tissue Oncology Society Annual Meeting; November 13-16, 2024. Abstract 380.
  7. Riedel RF, Agulnik M. Evolving strategies for management of desmoid tumor. Cancer. 2022;128:3027-3040.